Soleo and Mitsubishi Tanabe Enter Data-sharing Agreement for Radicava

Marisa Wexler, MS avatar

by Marisa Wexler, MS |

Share this article:

Share article via email
Covid-19 and ventilation

Mitsubishi Tanabe Pharma America (MTPA) and Soleo Health have entered into an agreement that will facilitate Soleo sharing real-world data about the use of MTPA’s Radicava (edaravone) in amyotrophic lateral sclerosis (ALS) patients.

Radicava was approved for the treatment of ALS by the U.S. Food and Drug Administration (FDA) in May 2017. The treatment is given by intravenous (into-the-vein) infusions, which usually takes about an hour, with a full course of treatment involving infusions several days in a row.

Soleo provides its customers with assistance administering specialty pharmaceuticals, including infusions like Radicava. The company has been doing so since August 2017, when the medicine became available in the U.S.

Soleo collects data using its SoleMetrics program, which compiles clinical data anonymously about diseases, drugs, etc. This real-world data can give interested parties — in this case, MTPA — useful information about the use of treatments and associated outcomes.

Under the collaboration agreement, Soleo has given MTPA data on 163 people with ALS who were treated with Radicava for at least three months. MTPA is analyzing the data to better understand how Radicava treatment affects the physical function of those who receive it, assessed using the ALS Functional Rating Scale-Revised (ALSFRS-R) score.

“Our collaboration with MTPA is just one example of the capabilities that SoleMetrics brings to drug manufacturers and the specialty pharmacy industry,” Drew Walk, CEO at Soleo, said in a press release announcing the collaboration.

“The real-world evidence we collect offers distinct insights into the patients’ journeys that we believe can be valuable to all stakeholders with whom we engage,” he said. “Most importantly, we are providing a critical service that we hope will improve the care we provide every day by applying and sharing the clinical and economic value of our data through SoleMetrics.”

Barbara Prosser, vice president of health outcomes and research at Soleo, said “Our clinical capabilities are the hallmark of how Soleo Health cares for its patients. The importance of clinical data for patient monitoring allows Soleo Health to establish best practices and deliver positive reporting outcomes. SoleMetrics affords us the ability to provide optimal care consistently while helping to improve the quality of life for the patients entrusted in our care.”